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ABSTRACT 
Intravenous immunoglobulin is a polyspecific immunoglobulin G preparation purified from 
plasma pools of several thousand healthy donors and its action on several components of the 
immune system is believed to have a modulation effect on the inflammatory process. Nowadays, 
it is standard as replacement therapy in primary immune deficiencies and some secondary immune 
deficiencies. Regarding IVIg mechanisms of action, there’s a rational for its potential use on 
treatment and management of infectious diseases. 
In this paper, were gathered several case reports, clinical trials and reviews present in the literature 
to date, where IVIg is used as treatment and management of different infectious diseases, and the 
outcomes described, discussing its potential beneficial effect.  
The information collected has shown there are no official recommendations on the use of IVIg in 
infectious diseases but are sometimes used off-label as adjunctive therapy. Depending on the 
disease, there are some reports describing possible improvement on patients’ outcome, whereas 
others report little or no change at all, with all lacking randomized, large-scale studies to support 
their results. 
For now, it remains only as a potential adjunctive therapy, waiting for more studies to confirm its 
valuable effect and understand the effect of several factors regarding the preparation and the 
patient which influence the outcome, in order to prove its true beneficial action, counterbalancing 
potential risks and high costs of this therapy. 
 
KEYWORDS: Intravenous immunoglobulins, Mechanism of action, Infectious diseases, Treatment, 
Management. 
 
RESUMO 
As imunoglobulinas intravenosas são uma preparação poliespecífica de imunoglobulina G, 
purificada de um conjunto de plasmas oriundos de milhares de dadores saudáveis e acredita-se 
que, devido às suas ações sobre vários componentes do sistema imune, poderá ter efeito 
modulatório no processo inflamatório. Nos dias de hoje, é usada como terapia de substituição 
padrão nas imunodeficiências primárias e em algumas secundárias. Tendo em conta os seus 
mecanismos de ação, existe uma base racional para o seu potencial uso no tratamento e 
abordagens das doenças infeciosas. 
Neste trabalho, foram reunidos diversos casos clínicos, revisões e ensaios clínicos presentes na 
literatura até á data, onde as IVIg são usadas no tratamento e abordagem de doenças infeciosas, e 
os seus desfechos clínicos e potenciais efeitos benéficos são aqui descritos e discutidos. 
A informação recolhida mostrou que não existem recomendações oficias para o uso de IVIg nas 
doenças infeciosas, mas são algumas vezes usadas off-label como tratamento adjuvante. 
Dependendo da doença, existem alguns trabalhos que descrevem uma possível melhoria no 
desfecho clínico dos pacientes, enquanto outros descrevem pouco ou até mesmo nenhum efeito, 
faltando estudos randomizados de larga escala para suportar os seus resultados em ambos os 
casos. 
Por agora, IVIg permanece como um potencial tratamento adjuvante, aguardando por estudos que 
confirmem o seu valor e para perceber o efeito de diversos fatores das preparações e do paciente 
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que influenciam o desfecho clínico, de modo a provar a sua verdadeira ação benéfica, 
contrabalançando os potenciais riscos e custos do tratamento. 
 
PALAVRAS-CHAVE: Imunoglobulinas intravenosas, Mecanismos de ação, Doenças infeciosas, 
Tratamento, Abordagem. 
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INTRODUCTION 
Intravenous immunoglobulin (IVIg) is a polyspecific immunoglobulin G preparation 
purified from plasma pools of several thousand healthy donors. IVIg preparation primarily 
contains human IgG molecules, with small amounts of IgA and IgM[1]. But then, how can a 
preparation with components present in every individual be able to elicit immunomodulation? 
The answer lays on two facts: first, the broad spectrum of specificities of IVIg, which reflect the 
immunologic experience of thousands of donors, cannot be found in any one individual. In fact, 
it has been reported variations in immune antibodies (Ab) titers from batch-to-batch, inherent to 
all IVIg preparations, which are important to be taken into consideration[2]. Secondly, therapeutic 
concentrations are four times higher than the endogenous ones, allowing a new steady state to be 
reached and saturation of target molecules and receptors follow, which cannot be reached under 
physiological conditions without the IVIg infusion.  
Nowadays, IVIg preparations are standard as a replacement treatment (low-dose therapy) 
of patients with primary immune deficiencies (PIDs) and some secondary immune deficiencies 
associated with hypo- and agammaglobulinemia[2], as it is believed to deliver missing immune 
antibodies against pathogens, allowing substitution or passive immunization against multiple 
bacteria and virus. Nevertheless, IVIg is increasingly being used beyond only as a substitution, 
but also for the treatment of a wide range of autoimmune and systemic inflammatory diseases[1, 
2]. It is also licensed as a high-dose therapy for patients with idiopathic thrombocytopenia 
purpura, Guillain-Barré syndrome, Kawasaki disease and chronic inflammatory demyelinating 
polyneuropathy, due to its anti-inflammatory actions[3]. 
In this paper, it will be summarized IVIg mechanisms of action and the rational for its 
potential use on treatment and management of infectious diseases as well as a review of its use 
and outcomes in different infectious diseases reported in the literature to date. 
 
MECHANISM OF ACTION 
Understanding the mechanisms by which IVIg modulates the immune system is 
particularly important in order to understand their possible beneficial action and to focus research 
on the most important characteristics. Direct neutralization of pathogenic immunoglobulins by 
preventing the binding of pathological antibodies to their targets is the first obvious mechanism. 
Nevertheless, it may be more complex than that. The immunoglobulins have two different 
regions: the F(ab)2 region, which contain the sites that  bind to antigens and therefore recognize 
specific foreign molecules; and the Fc region that, by binding to a specific class of Fc receptors 
and other immune molecules, such as complement proteins, plays an important role in modulating 
immune cell activity. 
IVIg and the receptors FcγRs and FcRn 
Via FcγRs, a class of receptors present on a variety of immune cells, these cells recognize 
the Fc region of IgG, which can generate intracellular activating or inhibitory signals.  There are 
four types of FcγRs, two of those have two subtypes each (FcγRI, FcγRII(A or B), FcγRIII(a or 
b) and FcγRIV). They are all activating receptors, except for FcγRIIB, which is an inhibitory 
receptor. The beneficial effects of high-dose IVIg therapy might be owing to the blockage and 
downregulation expression of activating FcγRs by monomeric IgG. This would prevent the 
binding of opsonized antigens, induction of effector functions, such as phagocytosis and secretion 
of pro-inflammatory cytokines by macrophages, degranulation of granulocytes and activation of 
dendritic cells (DC’s) by immune complexes. On the other hand, there is also evidence pointing 
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out the importance of IVIg on the modulation of the inhibitory receptor FcγRIIB, where the 
upregulation on ‘effector macrophages’ leads to their inactivation[1].  It’s also important to take 
into consideration a class of receptors crucial to IgG half-life: neonatal Fc receptors (FcRns). 
These receptors are expressed in the endosomal compartment of the intestinal epithelium, vascular 
endothelium and macrophages, and regulate serum IgG levels by binding pinocytosed IgG in the 
endosomes and recycling it to the cell surface, thereby rescuing it from degradation in lysosomes. 
High dose IVIg therapy leads to saturation of this receptor by IgG, resulting in enhanced clearance 
of pathogenic autoantibodies, which are replaced by IVIg's IgG coming from healthy donors[1, 
3]. 
IVIg and inhibition of complement factors 
  IgG present in IVIg binds to activated C3b and C4b through its Fc portion, thus a high 
concentration of soluble monomeric IgG may prevent the damage of tissue by deviation of the 
complement cascade from the target tissue to the ‘exogenous’ IgG in the circulation[3, 4]. IVIg 
can also bind and saturate the complement receptors CR1 and CR3 in activated macrophages thus 
preventing the destruction of target cells already bound by pathogenic antibodies[5]. 
IVIg and superantigen neutralization 
Superantigens can directly activate T cells by binding to the T cell receptor (TCR) through 
its Vβ region and at the same time by binding to the MHC class II molecules in a non-restricted 
mechanism. Thus, superantigens can lead to a major polyclonal response which can lead to serious 
clinical consequences. This response can be prevented by immunoglobulins present in IVIg (such 
as against TSST-1 and staphylococcal enterotoxins) which are capable of binding bacterial and 
viral superantigen epitopes as well as some Vβ regions on the TCR. Therefore, these anti-
microbial antibodies can be considered as immunomodulatory[2, 5]. 
IVIg and cytokine production modulation 
Physiologic autoantibodies to IL-6, IL-1, TNF-α, IL-8, GM-CSF and others have been 
found in healthy individuals. Consequently, IVIg contains natural anticytokine autoantibodies. It 
is possible that anti-inflammatory activities of IVIg are mediated by neutralizing overshooting 
pro-inflammatory cytokines, which may be responsible for an immediate relief of life-threatening 
condition associated with the rapid considerable elevation of cytokine levels[5]. 
IVIg and apoptosis modulation 
IVIg contains natural anti-Fas receptor autoantibodies which are able to block molecular 
Fas ligand/Fas receptor interactions and consequently prevent apoptosis (for example, preventing 
keratinocyte apoptosis which is beneficial in the treatment of patients with toxic epidermal 
necrolysis). However, it has also been reported agonistic anti-Fas receptor antibodies in IVIg 
preparations, which might indicate IVIg anti-inflammatory effects also by inducing apoptosis in 
inflammatory cells, such as activated T cells, neutrophils or eosinophils[2]. 
IVIg and differential antibody glycosylation  
IgG antibodies are glycoproteins that contain a sugar moiety attached to each of the 
asparagine 297 (N297) residues in the two chains of the antibody Fc fragment, forming part of 
the scaffold for FcγR binding. The importance of this sugar moiety is highlighted by the loss of 
therapeutic activity of deglycosylated IVIg preparations[3, 5]. 
IVIg and innate and adaptive immune system cells 
There is quite a range of changes induced by IVIg preparations on the different types of 
immune cells. These changes are summarized in figure 1. 
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ADVERSE EFFECTS 
The reason for IVIg adverse reactions is still not clear, although some studies have 
speculated it may be due to the antigenicity of the IgG itself, large molecular weight IgG 
aggregates, the presence of an antibody to a circulating microbial antigens or self-antigens, 
complement activation or direct release of cytokines from mononuclear cells[6]. The majority of 
studies to date have pointed out that beneficial effects of IVIg preparations lay on the action of 
monomeric IgG and that dimers and aggregates in IVIg preparations are believed to be responsible 
for its side effect, as multimeric IgG aggregates may activate FcRs unspecifically. Nevertheless, 
the evidence is emerging that IgG dimers or multimers, which are usually regarded as pro-
inflammatory compounds, can also mediate suppression of immune responses, as shown in 
different experimental models with idiopathic thrombocytopenia purpura[7] and Listeria 
monocytogenes infection[8]. Owing to the large donor pool and different manipulations during 
the purification process of IVIg, complexes of anti-idiotype antibodies with complimentary 
idiotypes can be formed. Therefore, therapeutic IVIg preparations should contain less than 1% of 
aggregates and 3–15% of IgG-dimers, the reason why several precautions are taken during the 
production process to keep the content of multimers minimal. However, in many instances, not 
the IgG preparation itself but rather product stabilizers such as sugar, salt content or denatured 
aggregated proteins are responsible for adverse effects[1, 3]. 
Control of donors and precautions in the IVIg manufacturing ensure an almost zero risk 
of transmission of infectious pathogens, including transmission of prions[9]. With the 
optimization of the concentration step techniques and strict control measures, the side effects of 
IVIg administration are relatively mild, transitory and occur during or just after IVIg infusion. 
Severe adverse events are rare and more frequently occur among patients with predisposing 
factors (advanced age, poor hydration, hypertension or reduced renal function) associated with 
higher doses of IVIg. Possible adverse effects, their onset time and possible approach are present 
in table 1. A careful selection of patients, clinical monitoring and a strict follow-up (or exclusion) 
of patients with predisposing factors are paramount to reduce the incidence of negative events as 
well as implement more specific measures such as slow infusion (in case of high doses, up to 8 
hours) and an adequate hydration before infusion, particularly in patients with impaired renal 
function and hypertension[6, 9]. It’s also important to remember that the content, composition 
and characteristics of each immunoglobulin preparation may vary, as mentioned before, and could 
adversely affect patients in a different manner, highlighting that an appropriate selection and 
administration of immunoglobulins should be individualized to yield the optimal outcome and to 
prevent adverse reactions[10]. 
 
IVIG USE IN INFECTIOUS DISEASES 
As seen, there are a lot of complex interactions between IVIg components and the 
different constituents of the immune system, many of them needing further studies. But can this 
immune system modulation be beneficial in case of infectious disease? The development of an 
infectious process involves the interaction between an infecting pathogen and the immune system 
of the host. If the immune response triggered by this interaction is inadequate, it can lead to the 
development of an overwhelming infection, while a vast release of the mediators can cause a 
systemic inflammatory response with serious consequences. Therefore, immunotherapy with 
IVIg preparations may have some advantages as an adjunctive agent to antimicrobial therapy, as 
it modulates the immune response, preventing its possible consequences if inadequate.  
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There are several reports in the literature about the IVIg use on infectious diseases, mainly 
as prophylaxis in immunosuppressed patients, and also the benefit on patients needing to receive 
immunosuppressant drugs, but with an infection which contraindicates them.  However, here we 
review IVIg use on immunocompetent patients with an established infectious disease and the 
outcomes with its use. 
IVIg use in sepsis 
Sepsis is a syndrome characterized by a systemic inflammatory response to infection that 
leads to rapid acute organ failure and potentially rapid decline to death, highlighting the 
importance to have powerful treatment options. The development of sepsis results from a complex 
interaction between the infecting microorganism and the host response and represents the harmful 
consequences of dysregulated immune response. Because of its anti-inflammatory and 
immunomodulating effect, IVIg has been proposed as an adjuvant therapy for sepsis, as well as 
in patients complicated with sepsis-induced coagulopathy (due to its effect on improving 
hemostatic abnormalities)[11], even though the clinical studies demonstrating their efficacy and 
safety are relatively small.  
Although the literature review suggests that polyclonal IVIg adjuvant therapy is 
associated with lower mortality rates, the evidence to support a routine IVIg use in the 
management of septic patients is inconclusive, mostly due to the large degree of heterogeneity in 
treatment effect between individual studies, as shown in Soares et al. meta-analyses[12]. This can 
be explained by the fact that the underlying pathophysiologic mechanisms in septic patients are 
highly individualized[13], and as such, individualized treatment is required. This may be achieved 
if trials take a number of potential confounding factors into consideration, concerning both the 
patient and the IVIg preparations, such as patient immunosuppression (previous or induced by 
sepsis) or the concentration and antimicrobial specificities of the antibodies contained in the 
batches of IVIg[14], currently not assessed and which could greatly affect the outcome. 
In addition to the small evidence of IVIg benefit use, its limited availability and high costs 
must also be considered. Soares et al. designed a study which assessed the clinical and cost-
effectiveness of IVIg in the UK National Health Service (NHS) and concluded that the existing 
heterogeneity between studies affected both the potential clinical and cost-effectiveness of IVIg 
treatment and, hence, current recommendations for its use[15]. Currently, present guidelines do 
not recommend the administration of IVIg in case of sepsis[16]. 
Regarding sepsis in neonates and infants, due to the immaturity of different organs and 
tissue and the need for invasive procedures (especially in preterm neonates), they are at special 
risk of sepsis. Initially, a study comparing control infants with infants with suspected infection, 
realized that after intravenous immunoglobulin treatment, the later had an increase concentration 
of total IgG (all subclasses) and complement component C4, and a decrease in C-reactive 
protein[17]. These results could confirm the rational basis for IVIg treatment in these cases. 
Afterward, several studies were conducted to confirm if this rational basis had, in fact, clinical 
effect. Some reported a reducing in early mortality rate, though with no significant effect on 
overall survival rate[18], outcome improvement when used as an adjunct to supportive and 
antibiotic therapy[19], while others reported no significant between-group difference in death 
rates and major disability nor significant differences in the incidence rates of subsequent sepsis 
episodes[20]. More recently, Ohlsson et al. latest systematic review concluded that routine 
administration of IVIg or IgM-enriched IVIg to prevent mortality in infants with suspected or 
proven neonatal infection is not recommended[21]. Notwithstanding, some authors still believe 
that passive immunotherapy is an attractive complementary strategy to fight neonatal sepsis and  
further studies should be designed with realistic outcomes using the immunoglobulin preparation 
with the best biological background[22]. 
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IVIg use in HIV infection 
Several lines of evidence suggest that increased tumor necrosis factor (TNF)-α activity 
also has an immunopathogenic role in HIV infection, in which its persistent activation may 
enhance HIV replication and may contribute to the development of immunodeficiency and to 
certain clinical manifestations in HIV-infected patients[23]. Thus, down-regulation of the 
abnormally increased TNF-α activity may be a potential therapeutic target and is thought to be 
achieved by IVIg administration, leading to a slower infection progression. Another action of the 
administration of IVIg was a temporary decrease in T cell activation and an increase in CD4+ T 
cell counts, suggesting that immunomodulating therapy in HIV-1 infection could indeed be 
effective[24]. 
Despite this effect on infection progression, the majority of studies conducted regarding 
HIV infection and IVIg use are as prophylaxis for opportunistic infection, as seen in De Simone 
et al. study where the cumulative probability of developing an opportunistic infection over the 12 
months of treatment in the group with only AZT were significantly higher than in the group with 
AZT associated with IVIg[25]. However, concerning the treatment of HIV-infected children with 
serious bacterial infections little supporting evidence is seen[26]. There are also some studies 
suggesting a positive effect of IVIg in other HIV associated disorders, such as 
thrombocytopenia[27] and myelopathy[28]. 
IVIg use in Influenza infection 
Complications or ultimately death arising from influenza infections are often associated 
with hyperinduction of proinflammatory cytokine production. Therefore, immunomodulatory 
therapies, such as IVIg, may be potential therapeutic strategies [29]. Evidence of a beneficial 
effect of IVIg therapy has been obtained in the 2009 H1N1 influenza infections, as severe 
infections were treated with hyperimmune IVIg (convalescent plasma fractionated from patients 
who recovered from the 2009 pandemic influenza A(H1N1)) within 5 days of symptom onset and 
were associated with a lower viral load and reduced mortality[30]. Other findings suggest that 
IVIg preparations contain antibodies that mediate antibody-dependent cellular cytotoxicity 
(ADCC) against heterologous influenza strains and may provide at least some level of protection 
for individuals at high risk of severe influenza disease[31] or even have a role as adjunctive 
therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted 
influenza strains, particularly in the immunocompromised[32]. 
IVIg use in Pneumonia 
Pneumonia is an inflammatory condition of the lung which can be caused by bacteria, 
virus, fungus or even parasites. Although the lack of studies of IVIg use in these situations, we 
can find some reports of successful use on refractory pneumonia with extrapulmonary 
manifestations due to macrolide-resistant Mycoplasma pneumoniae infection[33], on an adult 
varicella pneumonia complicated by acute respiratory distress syndrome[34], and a possible 
application in necrotizing Staphylococcus aureus pneumonia, as antibodies against the panton-
valentine leukocidin (PVL) of this bacteria responsible for pulmonary necrosis is contained in 
IVIg preparations[35]. Another mechanism for IVIg beneficial effect could be by improving the 
phagocytic activity via activation of the membrane immunoglobulin receptors of blood 
granulocytes and monocytes. However, these effects were not confirmed in ICU patients with 
nosocomial pneumonia[36]. In spite of its potential positive effect, IVIg hasn’t shown results on 
reducing mortality in more severe case, such as in mechanically ventilated pneumonia patients 
with septic shock[37]. 
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IVIg use in Clostridium difficile infections  
There have been several case reports describing severe and resistant Clostridium Difficile 
(C. Difficile) colitis with vast clinical symptoms improvement and successfully treated with 
IVIg[38-41]. The predominant mechanism of action for IVIg is thought to be by binding and 
neutralization of toxin A by IgG antitoxin A antibodies present in these formulations. Although 
overall appearance of the benefits of using IVIg, the small sample sizes and lack of control groups 
on  studies do not allow recommendations to be made regarding the use of immunoglobulin in C. 
difficile infection[42, 43]. Therefore, randomized trials to clarify the role of IVIg for the treatment 
of these infection and to evaluate the ideal dose, timing of administration and clinical 
characteristics of the patient population are needed.   
IVIg use in Parvovirus (HPV) B19 infections  
Symptoms caused by acute HPV-B19 infection can vary considerably from asymptomatic 
to severely symptomatic. Some reports describe IVIg therapy resulting in a remarkable 
improvement of symptoms and functional outcome in immunocompetent patients, such as on a 
case of severe arthritis associated with acute HPV-B19 infection[44], probably by suppression of 
TNF-α production in HPV-B19-infected immune cells that infiltrate the synovial tissues; on a 
case of HPV-B19 chronic infection with neurological impairment and arthritis[45]; on three cases 
of HPV-B19 infection in association with new-onset systemic necrotising vasculitis syndromes 
[46]; and on congenital pure red cell aplasia due to HPV-B19 infection in preterm infants[47], 
indicating a potentially curative role for IVIg in such disorders, due to the presence of B19 IgG 
neutralizing activity in these preparations[48]. 
There is also a series of three cases of chronic fatigue syndrome (CFS) that followed acute 
parvovirus B19 infection that, when treated with IVIg, led to clearance of parvovirus B19 viremia, 
resolution of symptoms and improvement in physical and functional ability in all patients, as well 
as the resolution of cytokine dysregulation[49]. However, a more recent case with similar 
characteristics reported symptoms persistence and also a paradoxical clinical response with 
increased viral replication after IVIg high-dose administration[50], suggesting a careful 
reconsideration for IVIg administration indication in the treatment of HPV-B19-associated CFS. 
IVIg use in Streptococcal Infections 
The major virulence mechanism of some strains of Group A beta hemolytic Streptococcus 
(GABHS) is the secretion of superantigens, such as streptococcal pyrogenic exotoxins (SPE)-A, 
SPE-B and SPE-C. Unlike traditional antigens, superantigens have the ability to stimulate 
immune cells without undergoing antigen processing and presentation by antigen presenting cells, 
and cause millions of T cells clones to be activated instead of just a few of them. The resultant 
excessive activation of cytokines, complement and clotting cascades, plus production of oxygen 
free radicals and nitric oxide, cause shock and multiorgan failure. Key roles are played by T cells 
and TNF, both α and β. The discovery that IVIg can reverse the hyperproliferation of T cells, 
neutralize superantigens and down-regulate the production of TNF is the basis for the treatment 
of GABHS infection manifestations, such as necrotizing fasciitis[51] and can also enhance 
systemic clearance of bacteria and neutrophil infiltrate into the infected tissues[52]. 
In invasive group A streptococcal infection (GAS), as in all rare diseases, large 
randomized clinical trials are most difficult to achieve, exemplified by Darenberg et al. European 
Randomized, Double-Blind, Placebo-Controlled Trial, which was prematurely terminated 
because of slow patient recruitment[53]. Therefore, there’s the need to rely on comparative 
observational data. Taken together with the high morbidity and mortality of these infections, as 
well as a detailed IVIg mechanism of action, observational studies results provide evidence for 
IVIg as a safe adjunctive therapy that contributes to increased survival in streptococcal toxic 
11 
 
shock syndrome (STSS)  and other manifestations of severe infection, and ought to be considered 
as treatment[54, 55]. In fact, there are several reports describing IVIg use in combination with 
antibiotics and surgery in cases of necrotizing fasciitis, toxic shock, and multisystem organ 
failure[56, 57]. Although it is difficult to assess the contribution of each part of the therapy, IVIg 
plus appropriate antimicrobials and surgery may be useful in the treatment of all forms of GAS 
infections when they are associated with STSS and also those attributable to group C and G 
streptococcal infection[58, 59]. Further prospective, randomized, clinical studies must be 
conducted to determine the most effective IVIg agent, timing, dose and length of therapy while 
taking into consideration that different preparations of IVIg may vary in their efficacy to 
neutralize streptococcal superantigens[60]. Also, highlight that patients in most of these studies 
and case reports were adults, and the scenario may be different in children, as seen in Shah et al. 
multicenter, retrospective cohort study, where IVIg use in children with STSS was not associated 
with improved outcomes but increased costs of their caring[61].  
IVIg use in infection-associated hemophagocytic syndrome (IAHS) 
Infection-associated hemophagocytic syndrome (IAHS) or also called reactive 
hemophagocytic syndrome (HS) is a form of the reactive hemophagocytic syndrome associated 
with viral, bacterial, fungal, mycobacterial, rickettsial and protozoal infections and with various 
malignant neoplasms. HS is a hyperinflammatory condition due to hyperactivation of 
lymphocytes and macrophages with resultant cytokine storm, leading to organ dysfunction and 
death. There are different pathological pathways, such as alteration of the activity of 
proinflammatory cytokines by binding of naturally occurring antibodies and the capacity of IVIg 
to alter cytokines release on a cellular level that may explain the variable therapeutic responses 
observed in HS associated with Dengue [62], with CMV[63], as a complication of acute hepatitis 
A virus infection[64] and in those with no etiologic agent identified[65]. However, due to IVIg 
high cost and the lack of strong evidence in such conditions, its use is limited to the most severe, 
life-threatening cases.  
IVIg use in Acute Disseminated Encephalomyelitis (ADEM)  
ADEM is an uncommon demyelinating disease of the central nervous system. It is thought 
to be an immune-mediated disease precipitated by various vaccinations and infectious agents. 
Usually no infectious agent is identified in ADEM, but it has been associated with viruses, such 
as herpes simplex, human immunodeficiency virus, human herpes 6, measles, hepatitis A or B, 
varicella, mumps, influenza, coxsackie virus, epstein-barr virus and cytomegalovirus, and also 
with bacteria, such as Group A hemolytic Streptococcus, Campylobacter, Salmonella, Chlamydia, 
Mycoplasma, Legionella, Leptospira, Borrelia burgdorferi, and Rickettsiae. The exact 
mechanism of action of IVIg in ADEM is not clear but it is thought to be more than one, such as 
by neutralizing the circulating antigen-antibody complexes and down-regulating pathologic 
cytokines production. It has been described the inclusion of IVIg in the treatment of ADEM 
secondary to Borrelia burgdorferi neuroborreliosis[66], a case report where the authors point out 
immunomodulation as the main responsible for the patient’s improvement, as it was observed a 
great recovery in the neurologic status days after IVIg administration; ADEM following a 
hepatitis A virus infection[67], with symptoms significant improvement as a response to the 
treatment; and in patients with post-infectious ADEM with no etiology identified[68, 69], also 
exhibiting clinical improvement, with return to their previous level of functioning. 
IVIg use in other infections  
Diverse case reports describe the successful use of IVIg in cases of encephalitis caused 
by several arboviruses and also by enterovirus, such as herpes simplex virus type I and Influenza 
A virus[70], with symptoms and neurological examination improvement. Another article suggests 
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that IVIg has contributed to decreasing the number of fatal cases of neonatal Coxsackie B viruses 
infection[71], due to the high titers of antibody to enteroviruses present in such preparations. 
However, the amount of anti-enteroviral antibody may not be the same in each batch, so it is not 
guaranteed the one used on treatment contains a sufficient amount of anti-enteroviral antibody, 
especially if there has not been an epidemic of the specific serotype that has infected a patient in 
his population[72]. 
There’s also some data indicating a possible benefit of IVIg in patients with a high 
probability of autoimmune disorders associated with HCV infection[73], as exogenously added 
Ig might modulate the immune network at various points, acting synergistically with IFNα. A 
case of fulminant Human parainfluenza viruses (HPIV)-2 myocarditis suggests clinicians should 
consider initiating ribavirin and IVIg in patients with HPIV myocarditis and persistent viremia 
not responding to supportive measures alone[74]. Also highlight a more rapid, more sustained 
and greater increase in platelet count with IVIg compared to placebo in cases of septic 
thrombocytopenia not associated with disseminated intravascular coagulation, leading the authors 
to recommend it in the septic patient who is bleeding or is likely to need invasive or surgical 
procedures[75].  
 
CONCLUSION 
Regarding IVIg known and described mechanisms of action, such as enhancing the 
clearance of antigens and modulation of the immune system, allied with the possible 
consequences of an overwhelming immune response, it presents with theoretical potential as 
adjunctive treatment and management of infectious diseases. 
In reality, due to the lack of randomized, large-scale studies, there’s no agreement in most 
of the results. There are no official recommendations in infectious diseases but IVIg is sometimes 
used off-label guided by some of the observational studies results. In most case reports present in 
the literature, IVIg is used as adjunctive therapy with no control group, making it difficult to 
surely assign the effect to one of the drugs used. 
For now, it remains only as a potential adjunctive therapy, waiting for more studies to 
confirm its valuable effect and understand the correct dose in each case, the concerns of batch-to-
batch differences and intrinsic factors of the patient, which can all influence the outcome, in order 
to prove its true beneficial action, counterbalancing potential risks and high costs of this therapy.  
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Table 1 
 
  
 Adverse effects 
Onset of 
reaction 
Comments 
Mild adverse effects 
(common, usually 
immediate) 
Infusion site pain, swelling, erythema 
Headache  
Myalgia, back pain, arthralgia  
Fever, chills, flushing  
Anxiety, malaise, fatigue 
Nausea, vomiting 
Hypotension, hypertension, tachycardia 
Immediate 
reaction 
Usually, resolve within the first few hours 
by stopping or reducing the infusion rate. 
 
May be relieved by standard anti-
inflammatory drugs and less commonly 
with corticosteroids. 
 
It may be necessary promethazine for 
nausea and vomiting, and narcotics for 
severe pain. 
Hyponatremia 
Neutropenia 
Direct Coombs’ positivity 
Delayed 
reaction 
Moderate adverse 
effects 
(less common, usually 
delayed) 
Persistent headache 
Aseptic meningitis 
Hemolytic anemia 
Serum sickness/arthritis 
Dermatologic complications 
Delayed 
reaction 
It can be helpful antimigraine 
medications for prolonged headache. 
Interference with vaccine effectiveness and/or 
immunodiagnosis 
Late reaction 
Severe adverse 
effects 
Anaphylactic/anaphylactoid reaction 
Immediate 
reaction 
 
Acute renal failure is associated with 
preparations containing sucrose. 
 
Acute cardiovascular events (stroke, acute 
myocardial infarction, thrombosis) are 
favored by the increased viscosity of the 
blood caused by IVIg (rare but clinically 
relevant). 
Renal complications 
Pulmonary complications 
Thrombosis/embolism 
Colitis 
Delayed 
reaction 
Blood borne Infectious diseases Late reaction 
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Table 1: IVIg adverse systemic reaction, which can be: immediate (60% of reactions) occurring 
during or within 6 hours of the infusion; delayed (40% of reactions) occurring 6 hours to 1 week 
after an infusion; or late (<1%) occurring greater than 1 week after or even weeks or months after 
an infusion. 
 
Figure 1: IVIg induced changes on the different types of immune cells. 
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    ­ Os autores recebem três separatas aquando da publicação do artigo. Podem ser fornecidas separatas adicionais, a expensas dos autores, quando requisitadas antes da
impressão.
    Pedido de publicação 
    ­ Os trabalhos deverão ser enviados à Redacção, em nome do editor, para a Unidade de Cuidados Intensivos Polivalenteda Urgência (UCIPU) do Hospital de São João ­ Porto.
Alameda Prof. Hernâni Monteiro ­ Porto. 
    Devem ser acompanhados de uma carta compedido de publicação, indicação da cedência do copyright e indicando que não foram publicados ou enviados para publicação em
outra revista nacional ou estrangeira, subscrito por todos os autores. Não serão aceites trabalhos já publicados ou enviados simultaneamente a outras revistas.
Nota final ­ Para um mais completo esclarecimento sobre este assunto aconselha­se a leitura dos requisitos do International Commitee of MedicalJournal Editors, resumidos nos números 4
e 5 do Boletim da S.P.P.R. epublicados na integra no N Eng J Med 1991; 324:424­428.
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